Current Management of DLBCL patients Undergoing CAR T-Cell Therapy
- Review outcomes of CAR T in RR-DLBCL with updates from the pivotal trials
- Highlight challenges in the management of pre-CAR T patients
- Discuss routine post-CAR T complications that can occur after the acute setting
Registration is complimentary for all healthcare professionals.
About the Faculty
Dr. Matthew Lunning
Bio coming soon!
Dr. John Kuruvilla
Dr. John Kuruvilla is an Associate Professor of Medicine at the University of
Toronto and a hematologist in the Division of Medical Oncology and Hematology
at the Princess Margaret Cancer Centre in Toronto. He is a member of the
Lymphoma, Autologous Transplant and Immune Effector Cell Therapy programs.
Dr. Kuruvilla’s research interest is the development of novel therapeutics in
lymphoid malignancies and incorporating translational research into clinical trials.
He is the Lymphoma Co-Chair for the Canadian Cancer Trials Group (CCTG) as
well as the Chair of the Scientific Advisory Board of Lymphoma Canada.